Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 |
| clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06964412 | The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy | active not recruiting | N/A | 36 | Brigham and Women's HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06523777 | PRISM: Patient Experiences With PET Imaging in Prostate Cancer(PRISM) | active not recruiting | — | 350 | Yale UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04070209 | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) | active not recruiting | Phase 2 | 66 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer(OU-SCC-EXCITE) | active not recruiting | Phase 1 | 15 | University of OklahomaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | active not recruiting | Phase 2 | 375 | BicycleTx LimitedINDUSTRY | 21 | May 27, 2026 | clinicaltrials |
| NCT07608419 | Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study(CZECH-PSMA) | active not recruiting | — | 400 | General University Hospital, PragueOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT02177292 | High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)(SIB) | active not recruiting | N/A | 80 | Medical College of WisconsinOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03582774 | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy(PSMA SRT) | active not recruiting | Phase 3 | 193 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04263025 | AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft | active not recruiting | Phase 2 / Phase 3 | 100 | Hackensack Meridian HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04731376 | Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone | active not recruiting | Phase 1 | 56 | Emory UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05496959 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study(LUNAR) | active not recruiting | Phase 2 | 93 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605507 | Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer(HYPOCx-iRex) | active not recruiting | N/A | 40 | Siriraj HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT01224288 | Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble | active not recruiting | Phase 3 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02799706 | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer(PEGASUS) | active not recruiting | Phase 3 | 885 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | May 22, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 98 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03291028 | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | active not recruiting | — | 15 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04216290 | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT05043090 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC(SAMETA) | active not recruiting | Phase 3 | 148 | AstraZenecaINDUSTRY | 25 | May 22, 2026 | clinicaltrials |
| NCT05359016 | Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique | active not recruiting | N/A | 9,014 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC(PRESERVE-006) | active not recruiting | Phase 1 / Phase 2 | 148 | OncoC4, Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT03987386 | Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 186 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04219904 | PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04634617 | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | active not recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05830838 | Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer(DAPPER) | active not recruiting | N/A | 50 | Mayo ClinicOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06035224 | Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 28 | RenJi HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00544830 | Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | active not recruiting | Phase 3 | 1,800 | Merck Sharp & Dohme LLCINDUSTRY | 32 | May 15, 2026 | clinicaltrials |
| NCT06043947 | Survival Monitoring in Russian Cancer Registries(SURVIMON) | active not recruiting | — | 100,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT07205497 | QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer(QNACTH) | active not recruiting | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02312557 | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | active not recruiting | Phase 2 | 58 | OHSU Knight Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03574571 | A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | active not recruiting | Phase 3 | 732 | Memorial Sloan Kettering Cancer CenterOTHER | 4 | May 14, 2026 | clinicaltrials |
| NCT04009148 | Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome | active not recruiting | — | 118 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | active not recruiting | Phase 3 | 755 | Merck Sharp & Dohme LLCINDUSTRY | 23 | May 14, 2026 | clinicaltrials |
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | active not recruiting | — | 500 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06970847 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer(AMPLIFY) | active not recruiting | Phase 3 | 220 | Clarity Pharmaceuticals LtdINDUSTRY | 2 | May 14, 2026 | clinicaltrials |
| NCT07581873 | Education and Health in Women With Cervical Cancer | active not recruiting | N/A | 28 | Federal University of MaranhaoOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04067713 | Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer(PARADIGM) | active not recruiting | — | 192 | University College, LondonOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2026source: clinicaltrials